Impact of Bevacizumab on Visual Function, Tumor Size, and Toxicity in Pediatric Progressive Optic Pathway Glioma: A Retrospective Nationwide Multicentre Study

SIMPLE SUMMARY: Around 30% of children with optic pathway glioma (OPG) require next order systemic anticancer therapy (SAT) in case of progression. Bevacizumab (BVZ) is considered an effective subsequent SAT for pediatric low grade glioma. This retrospective nationwide multicentre study evaluated th...

Descripción completa

Detalles Bibliográficos
Autores principales: Bennebroek, Carlien A. M., van Zwol, Judith, Porro, Giorgio L., Oostenbrink, Rianne, Dittrich, Anne T. M., Groot, Annabel L. W., Pott, Jan W., Janssen, Etienne J. M., Bauer, Noël J., van Genderen, Maria M., Saeed, Peerooz, Lequin, Maarten H., de Graaf, Pim, Schouten-van Meeteren, Antoinette Y. N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776082/
https://www.ncbi.nlm.nih.gov/pubmed/36551572
http://dx.doi.org/10.3390/cancers14246087

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776082/
https://www.ncbi.nlm.nih.gov/pubmed/36551572
http://dx.doi.org/10.3390/cancers14246087

Ejemplares similares